Statistical analysis of cost–effectiveness data from randomized clinical trials

Since the mid-1990s, motivated by the availability of patient-level cost data in randomized clinical trials, there has been rapid development in the statistical methods for analyzing cost-effectiveness data. Initial efforts concentrated on inference about the incremental cost-effectiveness ratio (ICER), but due to difficulties associated with ratio statistics, interest has settled more recently on incremental net benefit (INB). Regardless of …